BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32045390)

  • 21. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
    Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
    Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
    Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
    Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
    Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
    Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
    Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
    Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
    Schmoeckel E; Kirchner T; Mayr D
    Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positivity for GATA3 and TTF-1 (SPT24), and Negativity for Monoclonal PAX8 Expand the Biomarker Profile of the Solid Cell Nests of the Thyroid Gland.
    Gucer H; Mete O
    Endocr Pathol; 2018 Mar; 29(1):49-58. PubMed ID: 29313264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
    Ates Ozdemir D; Usubutun A
    Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
    Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
    Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
    Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
    Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
    Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
    Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of Immunophenotypic Panel to Differentiate Upper From Lower Gastrointestinal Adenocarcinomas: Analysis of New and Traditional Markers.
    Chauhan A; Sanchez-Avila M; Manivel J; Dachel S; Larson W; Hanson B; Gravely A; Mesa H
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):13-19. PubMed ID: 33295746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.
    Le Page C; Köbel M; Meunier L; Provencher DM; Mes-Masson AM; Rahimi K
    J Pathol Clin Res; 2019 Jul; 5(3):177-188. PubMed ID: 30924313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms.
    Uccella S; Facco C; Chiaravalli AM; Pettenon F; La Rosa S; Turri-Zanoni M; Castelnuovo P; Cerati M; Sessa F
    Endocr Pathol; 2022 Jun; 33(2):264-273. PubMed ID: 35522392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
    Berg KB; Schaeffer DF
    Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Young investigator challenge: Cadherin-17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?
    Brandler TC; Jelloul FZ; Soto D; Das K; Rosen L; Bhuiya TA
    Cancer Cytopathol; 2015 Dec; 123(12):706-13. PubMed ID: 26671737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Divergent Lineage Markers in Anaplastic Thyroid Carcinoma.
    Mneimneh WS; Asa SL
    Am J Surg Pathol; 2024 Feb; 48(2):230-237. PubMed ID: 37972932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy.
    Russell DH; Epstein JI; Kryvenko ON; Schlumbrecht M; Jorda M; Pinto A
    Arch Pathol Lab Med; 2024 Jun; 148(6):705-714. PubMed ID: 37948107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian metastases of intestinal-type gastric carcinoma: A clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor.
    Lerwill MF; Young RH
    Am J Surg Pathol; 2006 Nov; 30(11):1382-8. PubMed ID: 17063077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
    Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
    Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.